Kymera Therapeutics KYMR
NASDAQ KYMR
$134.84 -1.80 (-1.32%)
At close: Nov 11, 2026 · 4:00 PM EST

Kymera Therapeutics (KYMR) EV to CFO (2020 - 2021)

Updated

Kymera Therapeutics' (KYMR) EV to CFO stood at 31.57 in Q2 2021, up 73.1% from the prior quarter.

Analysis

Kymera Therapeutics (KYMR) EV to CFO (2020 - 2021) Analysis & Trends

On a TTM basis, Kymera Therapeutics' EV to CFO came in at 15.72 as of Jun 30, 2021; for FY2020, it was 8.84.

  • Per Business Quant, the preceding three quarters came in at 18.23 (Q1 2021), 8.84 (Q4 2020) and 3.84 (Q3 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Kymera Therapeutics 11.66 Bn 8.50 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 31.57
Mar 31, 2021 18.23
Dec 31, 2020 8.84
Sep 30, 2020 3.84
API Access

Kymera Therapeutics EV to CFO API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-cfo&ticker=KYMR&period=max&api_key=YOUR_API_KEY